Connect your AI

Omeros OMER Total Liabilities & Equity

Total Liabilities & Equity at other companies

Cullinan Therapeutics, Inc.CGEM

$402.98M-30.5%

Nektar TherapeuticsNKTR

$763.27M+198%

ImmunomeIMNM

$619.79M+80.9%

Vor BiopharmaVOR

$506.75M+364%

AnnexonANNX

$262.89M-13.2%

Arcus BiosciencesRCUS

$997M-13.8%

Other financials

Income statement

Revenue$9.9M—

Gross profit$29.7M—

Operating income-$40.9M-9.2%

Net income$56.1M+268%

EPS (diluted)-$0.59-20.4%

Balance sheet

Cash & equivalents$1.9M-55.3%

Total debt$13.5M-30.3%

Total equity-$63.3M+70.3%

Total assets$286.2M+21.7%

Cash flow

Operating cash flow-$14.5M+59.5%

CapEx--100%

Free cash flow-$14.5M+59.6%

Valuation

Market cap$765.73M+307%

P/S8.5×—

Profitability

Gross margin98.9%—

Operating margin-181.8%—

Net margin-136.6%—

FCF margin-121.6%—

Returns & leverage

Return on equity86.6%—

Debt / equity0.3×-1.1×

Current ratio3×+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Omeros's total liabilities & equity?: Omeros (OMER) reported total liabilities & equity of $286.17M in Q1 2026.
How has Omeros's total liabilities & equity changed year-over-year?: Omeros's total liabilities & equity increased by 21.7% year-over-year, from $235.16M to $286.17M.
What is the long-term trend for Omeros's total liabilities & equity?: Over 5 years (2020 to 2025), Omeros's total liabilities & equity has grown at a 12.5% compound annual growth rate (CAGR), from $181.04M to $325.63M.
What does total liabilities & equity mean?: Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.